Obesity makes joint-replacement surgery harder. Patients with higher body weight tend to face more complications during and after the procedure, and they often report worse pain and function once they have recovered. That gap has pushed researchers toward an obvious question: what if patients lost meaningful weight before going under the knife?
Weight-loss programs before surgery sound straightforward, but the evidence has been inconsistent. Diet and exercise advice alone rarely produces enough change in the months before a scheduled operation. A newer class of compounds called glucagon-like peptide-1 receptor agonists, or GLP-1 RAs, has attracted attention because the literature suggests they produce greater and more sustained reductions in body weight than lifestyle changes alone, while also influencing inflammation and metabolic markers.
A recently published trial protocol, appearing in Bone and Joint Open, describes a pilot randomized controlled trial that will test whether delivering a GLP-1 RA as a formal perioperative strategy is feasible, tolerable, and acceptable in older Asian adults with obesity who are scheduled for total knee arthroplasty. The trial is not yet reporting clinical results. What it offers right now is a detailed plan, and that plan itself reveals a lot about how researchers are thinking through this problem.
Why obesity complicates knee arthroplasty
Total knee arthroplasty, often called TKA or total knee replacement, is one of the most common orthopedic procedures worldwide. It relieves severe joint pain caused by osteoarthritis by replacing the damaged knee surface with an implant. Surgeons perform hundreds of thousands of these operations every year, and the outcomes are generally good.
Obesity changes that picture. The trial protocol notes that patients with obesity face higher rates of perioperative complications, including wound-healing problems, blood clots, and infection. They also tend to report more pain and poorer functional recovery after surgery compared with patients at lower body weights. The mechanical load on a replaced joint is one part of the problem, but researchers point to metabolic and inflammatory factors as well. Fat tissue produces signaling molecules that promote systemic inflammation, and that inflammation may independently worsen outcomes regardless of how much the knee itself weighs.
Preoperative weight loss has therefore seemed like a logical target. Trials of supervised diet programs before joint replacement have produced mixed results, and very few have used pharmacological weight-management tools. According to the published protocol, no randomized controlled trial has yet examined GLP-1 RAs specifically as a perioperative optimization strategy before TKA.
The GLP-1 receptor agonist mechanism
GLP-1 receptor agonists are peptide-based compounds that mimic the action of a naturally occurring gut hormone called glucagon-like peptide-1. That hormone is released after eating and acts on receptors in the brain, pancreas, and gut to slow digestion, reduce appetite, and improve glucose regulation.
When researchers give GLP-1 RA compounds to people over weeks or months, the literature shows meaningful reductions in body weight alongside improvements in blood sugar, blood pressure, and certain inflammatory markers. The compound used in this trial, referred to generically here as a semaglutide-class GLP-1 RA, has been studied extensively in metabolic-disease populations.
Importantly, the trial protocol acknowledges that weight loss alone may not explain all the potential effects around surgery. The researchers specifically plan to consider metabolic and anti-inflammatory pathways when interpreting results. That framing matters because it opens the possibility that reduced inflammation, improved insulin sensitivity, or other systemic changes could contribute to better surgical outcomes independently of how many kilograms a patient loses before their operation.
Trial design and participants
The study is a two-arm pilot randomized controlled trial. Researchers plan to enroll 54 adults between 40 and 80 years of age who have a body mass index at or above 27 kilograms per square meter and are already on the waiting list for a primary total knee arthroplasty. Participants will be split evenly: half will receive the GLP-1 RA plus standard TKA care, and half will receive usual care alone, which includes routine orthopedic management and standardized advice on diet and physical activity.
The intervention timeline is substantial. Participants assigned to the treatment arm will receive the GLP-1 RA for 48 weeks before surgery and then again for 48 weeks after surgery. A planned four-week washout period is built in both before and after the operation itself. That means the treatment is paused around the time of surgery, which reflects practical concerns about managing appetite and hydration around a major procedure.
The trial specifically focuses on older Asian adults. The protocol notes that no prior study of this kind has concentrated on an Asian population, which is a meaningful gap because body-composition norms, comorbidity patterns, and BMI thresholds for metabolic risk can differ across ethnic groups.
Primary and exploratory outcomes
Because this is a pilot trial, the main outcomes are about feasibility rather than clinical effectiveness. The researchers are primarily asking: can we recruit enough people, can participants stick to the protocol, do they tolerate the compound, and do they stay in the trial through completion? These feasibility metrics will determine whether a larger, fully powered trial is worth designing and funding.
The trial also tracks what the researchers call exploratory clinical outcomes. These include changes in body weight, pain levels, patient-reported functional outcomes, and perioperative complications. The word exploratory is important here. These results will help estimate effect sizes and variability for future trial planning. They are not powered to prove or disprove effectiveness on their own.
This two-level structure, feasibility first and clinical signals second, is a standard approach in early-phase randomized work. It prevents researchers from drawing firm conclusions from a sample too small to support them while still generating useful data that guides the next step.
What this protocol does not yet tell us
It is worth being clear about the limits of a published protocol. The trial record describes the methods, rationale, and planned analyses. It does not report results because data collection has not concluded. Any discussion of whether the GLP-1 RA will improve outcomes for these patients would be speculative at this stage.
The early data from metabolic-disease research that informs this trial showed effects in populations defined largely by type-2 diabetes or cardiovascular risk, not by surgical status. Whether those findings translate into better perioperative outcomes for older adults with knee osteoarthritis is precisely the question the trial is designed to begin answering.
Researchers also acknowledge that tolerability is genuinely uncertain in this context. GLP-1 RAs can cause nausea, vomiting, and reduced appetite, and those effects matter more when a patient is preparing for or recovering from major surgery. The four-week washout windows around the operation reflect that concern, and measuring tolerability is one of the primary trial objectives.
Broader context in perioperative research
This trial sits within a growing research interest in using metabolic interventions to optimize patients before elective surgery. The logic is that surgery is a planned event, unlike a cardiac emergency or trauma, so there is time to change a patient's physiological state beforehand. Preoperative optimization programs already exist for smoking cessation, anemia correction, and physical conditioning. Adding metabolic-peptide strategies to that toolkit is a natural extension of the same thinking.
The focus on inflammation is also consistent with a wider shift in how researchers understand obesity-related surgical risk. The older view centered on mechanical factors like excess load on joints and tissues. The newer view incorporates chronic low-grade inflammation and metabolic dysregulation as independent contributors to poor healing and recovery. GLP-1 RAs affect both of those pathways, which is part of why they are interesting in this surgical context.
If the pilot trial demonstrates good feasibility and generates effect-size estimates in the expected direction, it will provide the foundation for a larger definitive trial. That future trial would need to be powered to detect real differences in pain, function, or complication rates. For now, the literature is building its case one step at a time.
